NCT04951778View on ClinicalTrials.gov

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

PHASE1TerminatedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Interventions
DRUG

CC-91633

Administered orally according to the assigned treatment schedule

Trial Locations (9)

28041

Local Institution - 303, Madrid

41013

Local Institution - 304, Seville

63110

Local Institution - 105, St Louis

77030

Local Institution - 104, Houston

98104

Local Institution - 109, Seattle

02114

Local Institution - 107, Boston

02215

Local Institution - 101, Boston

08035

Local Institution - 302, Barcelona

08036

Local Institution - 301, Barcelona

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY